These data support the hypothesis that SPRY4-IT1 downregulation may serve as a possible diagnostic biomarker for NSCLC and may play various functions not only in the diagnostic but also in the follow-up process. This evidence concerns the gene SPRY4 and non-small cell lung carcinoma.